Conmed (NASDAQ: CNMD) reported Q3 EPS of $0.38, $0.06 worse than the analyst estimate of $0.44. Revenue for the quarter came in at $169.2 million versus the consensus estimate of $173.96 million.

Conmed sees FY2015 EPS of $1.65-$1.70, versus prior guidance of $1.82-$1.92 and the consensus of $1.83. Conmed sees FY2015 revenue of $715-720 million, versus prior guidance of $723-738 million and the consensus of $730.47 million.

For earnings history and earnings-related data on Conmed (CNMD) click here.